Squalamine - NeuBase Therapeutics
Alternative Names: EM0147; EVIZON; MSI-1256F; OHR 102; Squalamine lactateLatest Information Update: 28 Jul 2023
Price :
$50 *
At a glance
- Originator Genaera Corporation
- Developer Genaera Corporation; NeuBase Therapeutics
- Class Antineoplastics; Cholestanols; Eye disorder therapies; Lactates; Small molecules
- Mechanism of Action Angiogenesis inhibitors; Platelet-derived growth factor inhibitors; Vascular endothelial growth factor C inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Diabetic macular oedema; Diabetic retinopathy; Fibrodysplasia ossificans progressiva; Non-small cell lung cancer; Ovarian cancer; Prostate cancer; Retinal vein occlusion; Wet age-related macular degeneration
Most Recent Events
- 19 Jul 2023 EOM Pharmaceuticals plans a clinical trial in Retinal vein occlusion in USA (Ophthalmic) (EOM Pharmaceuticals website, July 2023)
- 24 Jun 2022 EOM Pharmaceuticals plans a confirmatory phase IIb trial in Wet-age related macular degeneration and Macular oedema in Mexico and India (Ophthalmic) in first quarter of 2023 (EOM Pharmaceuticals website, July 2023)
- 02 Dec 2021 EOM Pharmaceuticals plans a phase II trial for Diabetic retinopathy and Wet age-related macular degeneration (Ophthalmic)